No Data
Should Weakness in NeuroScientific Biopharmaceuticals Limited's (ASX:NSB) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Neuroscientific Biopharmaceuticals Secures US FDA Guidance for Glaucoma Medication
NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%
NeuroScientific Biopharmaceuticals Limited's (ASX:NSB) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
NeuroScientific Biopharmaceuticals (ASX:NSB) Secures $3.7m Tax Incentive Refund
No Data
